Clinical Trials · NCT01455896
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Intarcia Therapeutics
- Enrollment
- 4,156
- Start date
- Mar 2013
- Locations
- 42 sites, 9 countries
- Primary endpoint
- time to first occurrence of any event included in the MACE cardiovascular composite endpoint (CV death, non fatal MI, non fatal stroke, or hospitalization for unstable angina),